TY - JOUR T1 - Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies JF - Anticancer Research JO - Anticancer Res SP - 5845 LP - 5849 VL - 37 IS - 10 AU - KENJI KISHIMOTO AU - RYOJI KOBAYASHI AU - DAIKI HORI AU - HIROZUMI SANO AU - DAISUKE SUZUKI AU - KUNIHIKO KOBAYASHI Y1 - 2017/10/01 UR - http://ar.iiarjournals.org/content/37/10/5845.abstract N2 - Aim: The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies. Patients and Methods: A retrospective analysis was performed in 45 pediatric patients with hematological malignancies who received febuxostat (10 mg daily, n=20) or allopurinol (300 mg/m2 daily, n=25) as a prophylaxis for TLS. Results: A significant decrease of serum uric acid (UA) level was observed in patients with febuxostat over the first 2 days (6.6±3.8 mg/dl vs. 4.5±2.8 mg/dl, p<0.001). The febuxostat group also showed significant reduction of urinary UA/creatinine ratios during the first two days of treatment (0.98±0.85 vs. 0.51±0.26, p=0.010). No significant differences were observed between febuxostat-treated and allopurinol-treated patients regarding the percent change in serum UA level. Conclusion: Febuxostat had a notable effect in reducing serum UA level in children with hematological malignancies. ER -